3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
9
Completed
8
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Hereditary Sensory and Autonomic Neuropathies
1
Interventions
TIC10 compound
3
trastuzumab deruxtecan
2
umbralisib
1
ublituximab
1
pembrolizumab
1
infigratinib
1
enfortumab vedotin
1
duvelisib
1
blinatumomab
1
belumosudil
1
Rituximab
1
KD025
1
Gemcitabine
1
Crizotinib
1
Cisplatin
1
Carboplatin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Has announcements
×
Rituximab
×
Clear all
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA